187 related articles for article (PubMed ID: 22258279)
1. Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2.
Plowchalk DR; Rowland Yeo K
Eur J Clin Pharmacol; 2012 Jun; 68(6):951-60. PubMed ID: 22258279
[TBL] [Abstract][Full Text] [Related]
2. The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement.
van der Weide J; Steijns LS; van Weelden MJ
Pharmacogenetics; 2003 Mar; 13(3):169-72. PubMed ID: 12618594
[TBL] [Abstract][Full Text] [Related]
3. Prediction of inter-individual variability on the pharmacokinetics of CYP1A2 substrates in non-smoking healthy volunteers.
Haraya K; Kato M; Chiba K; Sugiyama Y
Drug Metab Pharmacokinet; 2016 Aug; 31(4):276-84. PubMed ID: 27318879
[TBL] [Abstract][Full Text] [Related]
4. A re-evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data.
Salem F; Johnson TN; Abduljalil K; Tucker GT; Rostami-Hodjegan A
Clin Pharmacokinet; 2014 Jul; 53(7):625-36. PubMed ID: 24671884
[TBL] [Abstract][Full Text] [Related]
5. Impact of Ethnicity-Specific Hepatic Microsomal Scaling Factor, Liver Weight, and Cytochrome P450 (CYP) 1A2 Content on Physiologically Based Prediction of CYP1A2-Mediated Pharmacokinetics in Young and Elderly Chinese Adults.
Li GF; Zheng QS; Yu Y; Zhong W; Zhou HH; Qiu F; Wang G; Yu G; Derendorf H
Clin Pharmacokinet; 2019 Jul; 58(7):927-941. PubMed ID: 30767128
[TBL] [Abstract][Full Text] [Related]
6. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking.
Faber MS; Fuhr U
Clin Pharmacol Ther; 2004 Aug; 76(2):178-84. PubMed ID: 15289794
[TBL] [Abstract][Full Text] [Related]
7. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia.
Ozdemir V; Kalow W; Posner P; Collins EJ; Kennedy JL; Tang BK; Albers LJ; Reist C; Roy R; Walkes W; Afra P
J Clin Psychopharmacol; 2001 Aug; 21(4):398-407. PubMed ID: 11476124
[TBL] [Abstract][Full Text] [Related]
8. Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test.
Tantcheva-Poór I; Zaigler M; Rietbrock S; Fuhr U
Pharmacogenetics; 1999 Apr; 9(2):131-44. PubMed ID: 10376760
[TBL] [Abstract][Full Text] [Related]
9. Severe 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) intoxication: insights into the measurement of hepatic cytochrome P450 1A2 induction.
Abraham K; Geusau A; Tosun Y; Helge H; Bauer S; Brockmöller J
Clin Pharmacol Ther; 2002 Aug; 72(2):163-74. PubMed ID: 12189363
[TBL] [Abstract][Full Text] [Related]
10. Assessment of CYP1A2 activity in clinical practice: why, how, and when?
Faber MS; Jetter A; Fuhr U
Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):125-34. PubMed ID: 16128905
[TBL] [Abstract][Full Text] [Related]
11. Theophylline has no advantages over caffeine as a putative model drug for assessing CYPIA2 activity in humans.
Rasmussen BB; Brøsen K
Br J Clin Pharmacol; 1997 Mar; 43(3):253-8. PubMed ID: 9088579
[TBL] [Abstract][Full Text] [Related]
12. Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance.
Ghobadi C; Johnson TN; Aarabi M; Almond LM; Allabi AC; Rowland-Yeo K; Jamei M; Rostami-Hodjegan A
Clin Pharmacokinet; 2011 Dec; 50(12):809-22. PubMed ID: 22087867
[TBL] [Abstract][Full Text] [Related]
13. Lack of correlation between fluvoxamine clearance and CYP1A2 activity as measured by systemic caffeine clearance.
Spigset O; Hägg S; Söderström E; Dahlqvist R
Eur J Clin Pharmacol; 1999 Feb; 54(12):943-6. PubMed ID: 10192755
[TBL] [Abstract][Full Text] [Related]
14. The effect of variable cigarette consumption on the interaction with clozapine and olanzapine.
Haslemo T; Eikeseth PH; Tanum L; Molden E; Refsum H
Eur J Clin Pharmacol; 2006 Dec; 62(12):1049-53. PubMed ID: 17089108
[TBL] [Abstract][Full Text] [Related]
15. Effect of age and smoking on in vivo CYP1A2, flavin-containing monooxygenase, and xanthine oxidase activities in Koreans: determination by caffeine metabolism.
Chung WG; Kang JH; Park CS; Cho MH; Cha YN
Clin Pharmacol Ther; 2000 Mar; 67(3):258-66. PubMed ID: 10741629
[TBL] [Abstract][Full Text] [Related]
16. Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes.
Djordjevic N; Ghotbi R; Bertilsson L; Jankovic S; Aklillu E
Eur J Clin Pharmacol; 2008 Apr; 64(4):381-5. PubMed ID: 18157525
[TBL] [Abstract][Full Text] [Related]
17. Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2.
Kinzig-Schippers M; Fuhr U; Zaigler M; Dammeyer J; Rüsing G; Labedzki A; Bulitta J; Sörgel F
Clin Pharmacol Ther; 1999 Mar; 65(3):262-74. PubMed ID: 10096258
[TBL] [Abstract][Full Text] [Related]
18. Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population.
Gunes A; Ozbey G; Vural EH; Uluoglu C; Scordo MG; Zengil H; Dahl ML
Pharmacogenomics; 2009 May; 10(5):769-78. PubMed ID: 19450128
[TBL] [Abstract][Full Text] [Related]
19. Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism.
Benowitz NL; Peng M; Jacob P
Clin Pharmacol Ther; 2003 Nov; 74(5):468-74. PubMed ID: 14586387
[TBL] [Abstract][Full Text] [Related]
20. Effects of the aqueous extract from Salvia miltiorrhiza Bunge on caffeine pharmacokinetics and liver microsomal CYP1A2 activity in humans and rats.
Wang X; Yeung JH
J Pharm Pharmacol; 2010 Aug; 62(8):1077-83. PubMed ID: 20663043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
